Search results for "Staging."

showing 10 items of 715 documents

Prognosis after surgery for multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: Functionality matters

2021

Contains fulltext : 245221.pdf (Publisher’s version ) (Open Access) BACKGROUND: Metastasized pancreatic neuroendocrine tumors are the leading cause of death in patients with multiple endocrine neoplasia type 1. Aside from tumor size, prognostic factors of pancreatic neuroendocrine tumors are largely unknown. The present study aimed to assess whether the prognosis of patients with resected multiple endocrine neoplasia type 1-related nonfunctioning pancreatic neuroendocrine tumors differs from those with resected multiple endocrine neoplasia type 1-related insulinomas and assessed factors associated with prognosis. METHODS: Patients who underwent resection of a multiple endocrine neoplasia ty…

AdultDiagnostic ImagingMalemedicine.medical_specialtyAdolescentBiopsy030230 surgeryNeuroendocrine tumorsGastroenterologyArticleYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineBiopsyTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]Multiple Endocrine Neoplasia Type 1medicineHumansMEN1Neoplasm MetastasisChildMultiple endocrine neoplasiaLymph nodeInsulinomaAgedNeoplasm StagingCause of deathAged 80 and overmedicine.diagnostic_testbusiness.industryLiver NeoplasmsHazard ratioDisease ManagementMiddle AgedPrognosismedicine.diseaseReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Pancreatic NeoplasmsPatient Outcome AssessmentNeuroendocrine Tumorsmedicine.anatomical_structure030220 oncology & carcinogenesisFemaleSurgeryDisease SusceptibilityNeoplasm GradingbusinessBiomarkers
researchProduct

Magnetically labeled water perfusion imaging of the uterine arteries and of normal and malignant cervical tissue: initial experiences.

1998

Purpose: The aim of this pilot study was to evaluate a magnetically labeled water perfusion imaging technique as a non-contrast-enhanced approach to demonstrate the uterine artery, its branches, and to assess the cervical uterine blood flow in healthy volunteers and in patients with advanced uterine cervical carcinoma (FIGO IIB-IVA). Methods and Materials: Seven healthy volunteers (mean age, 29 years) and twenty-two patients (mean age, 52 years) with advanced cancer of the uterine cervix (FIGO IIB-IVA) were prospectively examined by magnetically labeled water perfusion imaging at different inversion delay times (300–900 ms). The magnetic resonance imaging (MRI) findings of all patients were…

AdultGadolinium DTPAPathologymedicine.medical_specialtyBiomedical EngineeringBiophysicsHemodynamicsContrast MediaUterine Cervical NeoplasmsPerfusion scanningCervix UteriSensitivity and Specificitymedicine.arterymedicineHumansRadiology Nuclear Medicine and imagingUterine arteryCervixAgedNeoplasm Stagingmedicine.diagnostic_testNeovascularization Pathologicbusiness.industryUterusHemodynamicsWaterMagnetic resonance imagingBlood flowArteriesMiddle AgedImage EnhancementMagnetic Resonance ImagingPerfusionmedicine.anatomical_structureDynamic contrast-enhanced MRIFemaleNuclear medicinebusinessPerfusionBlood Flow VelocityMagnetic resonance imaging
researchProduct

Peritoneal HPV‐DNA test in cervical cancer (PIONEER study): A proof of concept

2020

The aim of this study was to investigate the prevalence of peritoneal human papillomavirus (HPV) infection in different clinical cervical cancer (CC) settings, and its association with potential clinical and/or histological factors. This is a single-center, prospective, observational study. Consecutive patients with newly diagnosed or recurrent/persistent CC, between March 2019 and April 2020, were included. A group of patients undergoing surgery for benign gynecological conditions was included as control group. All patients underwent HPV-DNA test in the cervix and in the peritoneal cavity simultaneously at time of surgery. Two-hundred seventy-two patients had cervical and peritoneal HPV te…

AdultHPVCancer Researchmedicine.medical_specialtyMultivariate analysiscervical cancergenotypemedicine.medical_treatmentUterine Cervical Neoplasmsprognostic factors.GastroenterologyHuman Papillomavirus DNA Tests03 medical and health sciencesPeritoneal cavity0302 clinical medicinegenotypesInternal medicineGenotypemedicineHumansProspective StudiesStage (cooking)Peritoneal CavityCervixAgedNeoplasm StagingAged 80 and overCervical cancerHuman papillomavirus 16Human papillomavirus 18business.industryHPV infectionprognostic factorsMiddle Agedperitoneummedicine.diseaseCervical conizationinfectionSettore MED/40 - GINECOLOGIA E OSTETRICIAmedicine.anatomical_structureOncology030220 oncology & carcinogenesisFemalebusinessInternational Journal of Cancer
researchProduct

How to select early-stage cervical cancer patients still suitable for laparoscopic radical hysterectomy: a propensity-matched study

2020

Background: Recently, it was reported that minimally invasive surgery (MIS) has a negative impact on early-stage cervical cancer (ECC) patient survival. At the same time, advantages of MIS regarding quality of life and low rate of intra- and postoperative complications are well known. Therefore, it is essential to select patients who may benefit from MIS without worsening their oncologic outcomes. The aim of this study is to investigate which pathological factors could guide surgeons’ choice about the best approach in ECC. Patients and Methods: Patients with 2009 FIGO stage from IA1 with lymphovascular space invasion (LVSI) to IB1/IIA1 treated by open or laparoscopic surgery were judged eli…

AdultLaparoscopic surgerymedicine.medical_specialtymedicine.medical_treatmentlaparoscopyUterine Cervical NeoplasmsHysterectomyDisease-Free Survivalopen surgeryYoung Adult03 medical and health sciences0302 clinical medicineSurgical oncologymedicineHumansMinimally Invasive Surgical ProceduresRadical HysterectomyPropensity ScoreLaparoscopyGrading (tumors)minimally invasive surgeryAgedNeoplasm StagingRetrospective StudiesAged 80 and overCervical cancermedicine.diagnostic_testbusiness.industryParametrialCervical cancer; laparoscopy; minimally invasive surgery; open surgery; radical hysterectomy; tumor diameterHazard ratioMiddle Agedmedicine.diseaseSurgerySurvival RateTreatment OutcomeSettore MED/40 - GINECOLOGIA E OSTETRICIAItalyOncology030220 oncology & carcinogenesisradical hysterectomyCervical cancerFemale030211 gastroenterology & hepatologySurgerytumor diameterbusiness
researchProduct

Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver

2012

To report the outcome of patients with hepatocellular carcinoma (HCC) in non-cirrhotic liver depending on the mode of primary treatment and to define clinicopathological factors influencing patients' prognosis.A retrospective analysis of an unselected cohort of 105 patients was performed. Overall survival (OS) was estimated by the Kaplan-Meier method and potentially prognostic factors were analyzed in Cox regression models.OS of the whole cohort at 1, 3, and 5 years was 66%, 47%, and 29%, respectively. Tobacco consumption, ECOG0, macroscopic vascular invasion, continuous tumor diameter, and treatment other than resection were predictors of decreased OS in the whole cohort. Resection was per…

AdultLiver CirrhosisMaleOncologymedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentAntineoplastic AgentsRisk FactorsInternal medicinemedicineCarcinomaHepatectomyHumansSurvival analysisAgedNeoplasm StagingRetrospective StudiesAged 80 and overProportional hazards modelbusiness.industryLiver NeoplasmsGastroenterologyRetrospective cohort studyMiddle AgedPrognosismedicine.diseaseSurvival AnalysisBCLC StageTreatment OutcomeLiverHepatocellular carcinomaCohortFemaleHepatectomybusinessFollow-Up StudiesScandinavian Journal of Gastroenterology
researchProduct

Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.

2006

AIM: To evaluate the immunohistochemical localization of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) on tumor tissue specimens from patients with hepatocellular carcinoma (HCC) and the serum levels of IL-6 and sIL-6R in a group of patients with HCC as well as liver cirrhosis (LC) in a group of patients with LC alone and in a control group. METHODS: Three groups of subjects were studied: group I (n = 83) suffering from HCC and LC, group II (n = 72) suffering from LC alone and group III (n = 42) as healthy controls. All patients had hepatitis C virus infection. Serum IL-6 and IL-6R levels were determined using a commercially available ELISA kit. Immunohistochemistry was performed using the…

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentChronic liver diseaseGastroenterologyInternal medicineCarcinomaMedicineHumansInterleukin 6ReceptorCytokineAgedNeoplasm Stagingbiologybusiness.industryInterleukin-6Chronic liver diseaseLiver NeoplasmsGastroenterologyGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistryReceptors Interleukin-6digestive system diseasesCytokineHepatocellular carcinomabiology.proteinImmunohistochemistryFemalebusinessRapid CommunicationWorld journal of gastroenterology
researchProduct

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractor…

2018

AbstractPurpose:Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor.Patients and Methods:Patients age ≥18 years with advanced solid tumors for which standard antineoplastic therapy was no longer effective were enrolled (NCT01703481). Parts 2 to 4 employed molecular screening for activating FGFR genomic alterations. In patients with such alterations, two selected doses/schedules identified during part 1 dose-escalation [9 mg once daily and 10 mg intermittently (7 days on/7 days off), as previously published (Tabernero JCO 2015;33:3401-8)] were tested.Results:The study included 187 patients. The most common treatment-related adverse events were…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyAdministration OralAntineoplastic AgentsDrug resistanceGastroenterologyYoung Adult03 medical and health sciencesHyperphosphatemia0302 clinical medicineRefractoryErdafitinibNeoplasmsQuinoxalinesInternal medicinemedicineHumansNeoplasmDosingAdverse effectProtein Kinase InhibitorsAgedNeoplasm StagingAged 80 and overbusiness.industryGenetic VariationMiddle AgedPrognosismedicine.diseaseReceptors Fibroblast Growth FactorTreatment Outcome030104 developmental biologyOncologyTolerabilityDrug Resistance Neoplasm030220 oncology & carcinogenesisRetreatmentPyrazolesFemalebusinessClinical Cancer Research
researchProduct

EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness

2020

The finding of novel molecular markers for prediction or prognosis of invasiveness in colorectal cancer (CRC) constitutes an appealing challenge. Here we show the up-regulation of EPDR1 in a prospective cohort of 101 CRC patients, in a cDNA array of 43 patients and in in silico analyses. EPDR1 encodes a protein related to ependymins, a family of glycoproteins involved in intercellular contacts. A thorough statistical model allowed us to conclude that the gene is significantly up-regulated in tumour tissues when compared with normal mucosa. These results agree with those obtained by the analysis of three publicly available databases. EPDR1 up-regulation correlates with the TNM staging parame…

AdultMale0301 basic medicineEpithelial-Mesenchymal TransitionColorectal cancerIn silicolcsh:MedicineNerve Tissue ProteinsBiologyArticle//purl.org/becyt/ford/3.3 [https]03 medical and health sciences0302 clinical medicinemedicinecancerHumansNeoplasm InvasivenesshumanProspective StudiesEpithelial–mesenchymal transitionlcsh:ScienceAgedCell ProliferationNeoplasm StagingcolorectalAged 80 and overRegulation of gene expressionMultidisciplinaryCell growthlcsh:RMethylationMiddle Agedmedicine.diseaseColorectal cancerNeoplasm ProteinsUp-RegulationEPDR1Gene Expression Regulation Neoplastic030104 developmental biologyCpG siteCell culture030220 oncology & carcinogenesisCancer research//purl.org/becyt/ford/3 [https]Femalelcsh:QColorectal NeoplasmsTranscriptionScientific Reports
researchProduct

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients

2018

In this study, the circulating miRNome from diagnostic neuroblastoma serum was assessed for identification of noninvasive biomarkers with potential in monitoring metastatic disease. After determining the circulating neuroblastoma miRNome, 743 miRNAs were screened in 2 independent cohorts of 131 and 54 patients. Evaluation of serum miRNA variance in a model testing for tumor stage, MYCN status, age at diagnosis, and overall survival revealed tumor stage as the most significant factor impacting miRNA abundance in neuroblastoma serum. Differential abundance analysis between patients with metastatic and localized disease revealed 9 miRNAs strongly associated with metastatic stage 4 disease in b…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyAdolescentTransplantation HeterologousMedizinDiseaseMiceNeuroblastomaYoung Adult03 medical and health sciencesInternal medicineNeuroblastomamicroRNABiomarkers TumormedicineAnimalsHumansCirculating MicroRNANeoplasm MetastasisStage (cooking)ChildAgedNeoplasm StagingNoninvasive biomarkersAged 80 and overbusiness.industryGeneral MedicineMiddle AgedSerum samplesmedicine.diseaseMicroRNAsCirculating MicroRNA030104 developmental biologyChild PreschoolLocalized diseaseFemalebusinessResearch Article
researchProduct

High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal c…

2018

Papillary renal cell carcinoma (PRCC) is currently divided in 2 subtypes. We reviewed a large cohort of PRCC and correlated subtype, morphological features and diagnostic marker expression with overall survival (OS) to uncover differences between the 2 subtypes. Three hundred seventy-six renal tumors initially diagnosed as PRCC with clinical and survival data were collected from the participating centers. Two hundred forty-six tumors were classified as PRCC1 (65.4%) and 130 as PRCC2 (34.6%) and graded according to the 2016 World Health Organization/International Society of Urological Pathology grading system. Morphological features (abundant cytoplasm, necrosis, fibrous stroma, foamy macrop…

AdultMale0301 basic medicinemedicine.medical_specialtyPathologyAdolescentPsammoma bodyPathology and Forensic MedicineMetastasisYoung Adult03 medical and health sciences0302 clinical medicineRenal cell carcinomamedicineHumansStage (cooking)ChildCarcinoma Renal CellAgedCell ProliferationNeoplasm StagingAged 80 and overTissue microarrayPapillary renal cell carcinomasbusiness.industryMiddle AgedPrognosismedicine.diseaseKidney Neoplasms030104 developmental biology030220 oncology & carcinogenesisImmunohistochemistryFemaleHistopathologybusinessHuman Pathology
researchProduct